Skip to content
AwardedCzechiaGoodsCZK 12,571,000

Selektivní Imunosupresiva - Tofacitinib II.

Published
Published 12 December 2024
Deadline
Closed 15 January 2025

Overview

The Institute of Clinical and Experimental Medicine procured selective immunosuppressive drug supplies containing tofacitinib (ATC L04AA29) for treating patients with ulcerative colitis according to approved indications. The contract was awarded to PHOENIX lékárenský velkoobchod, s.r.o. for 12,569,771.5 CZK in January 2025.

Key details

Country
Czechia
Status
Awarded
Category
Goods
Estimated value
CZK 12,571,000
Procedure
Open
SME suitable
Yes
Published
12 December 2024
Deadline
Closed
Classification (CPV)
Immunosuppressive agents

Award outcome

Awarded value
CZK 12,569,772
Award date
22 January 2025
Contract period
17 February 2025 → 27 January 2029
Winner
  • PHOENIX lékárenský velkoobchod, s.r.o.

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    13 February 2025

  2. Contract Notice

    12 December 2024

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Selektivní Imunosupresiva - Tofacitinib II. — won by PHOENIX lékárenský velkoobchod, s.r.o. — Skim